Edition:
United States

CorMedix Inc (CRMD.A)

CRMD.A on American Stock Exchange

0.43USD
2:12pm EDT
Change (% chg)

$0.02 (+5.70%)
Prev Close
$0.40
Open
$0.41
Day's High
$0.43
Day's Low
$0.41
Volume
18,490
Avg. Vol
46,292
52-wk High
$3.25
52-wk Low
$0.32

Chart for

About

CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate,... (more)

Overall

Beta: -0.32
Market Cap(Mil.): $24.53
Shares Outstanding(Mil.): 61.02
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

BRIEF-Cormedix Q2 net loss of $0.10 per share​

* Cormedix Inc - ‍for Q2 2017, Cormedix recorded a net loss of $0.10 per share​

Aug 09 2017

BRIEF-Cormedix Inc provides update on Neutrolin ongoing Phase 3 clinical trial

* Cormedix inc provides update on Neutrolin ongoing Phase 3 clinical trial following FDA correspondence

Aug 02 2017

BRIEF-Cormedix inc qtrly loss per share $0.19

* Says in discussion with FDA regarding possible prospective changes to lock-it 100 trial protocol

May 10 2017

BRIEF-CVI Investments Inc reports 6.7 pct passive stake in Cormedix Inc

* CVI Investments Inc reports 6.7 percent passive stake in Cormedix Inc as on April 28, 2017 - SEC filing Source text (http://bit.ly/2pdxeS1) Further company coverage:

May 08 2017

BRIEF-Cormedix announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC Filing

* Cormedix Inc- Announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC filing

Apr 20 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.64 -1.58
Pfizer Inc. (PFE.N) $35.96 -0.04
Merck & Co., Inc. (MRK.N) $65.56 -0.23
Abbott Laboratories (ABT.N) $51.60 -0.29
Sanofi SA (SASY.PA) €83.87 +1.57
Eli Lilly and Co (LLY.N) $83.21 +1.19

Earnings vs. Estimates